Corporate VCs back Syntaxin's £18 million C round
This article was originally published in Scrip
Executive Summary
Syntaxin, the UK biotech company focused on developing biopharmaceuticals to control cell secretion, has bolstered its corporate VC investor list by turning to Lundbeckfond Ventures and Ipsen in an £18 million series C round.